Latest news with #MDS
Associated Press
2 days ago
- Business
- Associated Press
Improving Data Center Sustainability With Cisco MDS 9000 Transceiver Power-Control Capability
In the fast-paced evolution of data centers, the spotlight on sustainability has never been brighter. As energy demands surge, finding innovative ways to reduce energy consumption becomes crucial. The transceiver power-control feature within Cisco MDS 9000 switches helps architecting sustainability in storage area networks and contributes to the broader goal of creating more environmentally responsible and cost-effective data center operations. The Power Challenge in Data Centers Modern data centers face a formidable challenge in managing escalating power demands. The sheer volume of servers, networking equipment, and storage arrays requires a substantial energy supply, leading to increased operational costs and a larger carbon footprint. The boom of Artificial Intelligence (AI) workloads and their power-hungry underlying infrastructure has changed trajectory and further exacerbated the situation. Addressing this challenge has become imperative for organizations striving for sustainability. In the journey toward net zero, Scope 2 greenhouse gas (GHG) emissions present a major hurdle for data center operators. With IT gear and network devices operating 24×7, their usage phase is the main contributor to GHG emissions. For network devices, the power demand of optical transceivers continues to rise. An SFP+ transceiver can reach 1.5 Watts, while a QSFP-DD transceiver can exceed 16 Watts. As a result, optical transceivers account for a significant portion of the energy consumption in modern switches and routers. In a typical 1RU switch, optical transceivers could represent 16% or more of its energy consumption under standard operating conditions. Understanding Transceiver Power-Control Feature Cisco MDS switches harness the advantages of the transceiver power-control feature to achieve a harmonious balance between performance and energy efficiency. This new capability represents an innovation for the entire industry. Organizations can experience a notable reduction in energy costs, contributing to operational savings while simultaneously lessening their environmental impact. Typically, when optical transceivers are inserted into switch ports and a user administratively shuts down a specific port, the switch only disables the laser without cutting off power to the optical transceiver. This means that when the port is shut down, the optical transceiver still draws significant power despite a slight reduction. Starting with Cisco MDS 64G platforms (DS-X9748-3072K9, MDS 9124V, MDS 9148V, and MDS 9396V), there is an SFP FPGA hardware support for controlling power to the transceiver at the per-port level. The transceiver power-control feature utilizes this hardware capability to turn off the power to the transceiver when a port is administratively shutdown. Upon an administrator performing a 'no shutdown' on a port, the power is restored to that transceiver. Older Cisco MDS platforms, as well as competitive solutions, do not have this hardware capability and cannot turn off the power when a port is administratively down. With Cisco MDS NX-OS Release 9.4(2) onwards, the transceiver power-control feature is available and enabled by default on all MDS 64G platforms. With this feature, ports are always-ready, not always-on. In other words, a port is always ready to be powered up, but when administratively down, the port would stay powered off and consume no energy. Lab tests show that 34 Watts of power are saved for 24 ports in the admin down state with their short-wave transceiver being powered off. Higher savings are achieved with long-wave transceivers. One practical scenario sees a customer with 6000 ports having 20% of spare ports. The transceiver power-control feature leads to about 1680W saved, equivalent to 14717 kWh/year. For a data center with PUE = 1.5 and assuming 0,27 euro/kWh, this translates into 5960 euro of savings in the energy bill each year. One feature, many benefits The transceiver power-control feature is an example of static power control, well-suited for networking devices, where planning for additional connectivity is possible. Customer evidence shows that spare ports account for 10% to 50% of all installed switching ports, indicating that transceiver power-control could drive substantial energy savings. The transceiver power-control feature has many benefits, including: Enabling/Disabling Transceiver Power-Control Feature The transceiver power-control feature is enabled by default on Cisco MDS 64G fibre channel switches. The feature can be turned on using the following CLI command: Enable/disable status of the feature can be viewed using the below CLI command. Transceiver power status for each port is displayed in the 'show interface' CLI command output. In the example below, interface fc1/3 shows that transceiver power-control feature is enabled, and the port is administratively shut. As a result, its power would be zero. Conclusion The deployment of Cisco MDS switches supporting the transceiver power-control feature represents a proactive step towards creating more sustainable and cost-effective data center operations. The potential benefits include energy savings, reduced energy bills, improved compliance with environmental standards, and a positive contribution to a more sustainable future. View original content here. Visit 3BL Media to see more multimedia and stories from Cisco Systems Inc.
Yahoo
3 days ago
- Business
- Yahoo
Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med Investment Forum 2025 in Abu Dhabi
ABU DHABI, UAE, May 28, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that target the innate immune system, announces that CEO Dr. David Bearss will serve as keynote speaker at the Med Investment Forum 2025. The event will take place on May 29, 2025, at the Rotana Beach Hotel in Abu Dhabi, UAE. Dr. Bearss will present: "Pioneering a New Era of Medicine by Unlocking the Body's Power of Genetic Resilience." The keynote will explore how insights from resilient individuals—those who remain disease-free despite genetic risk—are reshaping therapeutic development. Halia's research, grounded in population-scale genomic data, is enabling breakthrough treatments for inflammatory and neurodegenerative diseases. "The key to solving medicine's toughest challenges lies in understanding why certain individuals are protected from disease," said Dr. Bearss. "At Halia, we're using that insight to design therapies that reprogram the body's immune response at the molecular level, ushering in a new era of precision immunology." Advancing Precision Immunology Through Genetic Resilience Halia Therapeutics is redefining how inflammation drives severe medical conditions through cutting-edge science and a robust development pipeline. The company's lead programs include HT-6184, a NEK7 allosteric modulator in clinical trials for myelodysplastic syndromes (MDS) and obesity, and HT-4253, designed to replicate the protective genetic effect of RAB10 loss-of-function in APOE4 homozygotes who show resilience to Alzheimer's disease. The Med Investment Forum, held under the patronage of the UAE Ministry of Health and Prevention in partnership with the World Health Organization (WHO), serves as a premier global platform connecting health ministers, investors, biotech leaders, and healthtech innovators. Halia's keynote participation underscores the innovation and global impact the Forum champions. The event offers an opportunity to discover transformative biotech solutions and connect with investors and decision-makers who are shaping the future of healthcare. Event Details Date: May 29, 2025 Location: Rotana Beach Hotel, Abu Dhabi, UAE Website: About Halia Therapeutics Halia Therapeutics is a clinical-stage biopharmaceutical company developing therapies that modulate the innate immune system to treat inflammation-driven diseases. By uncovering the biology behind genetic resilience, Halia designs breakthrough treatments for neurodegeneration, hematological disorders, and metabolic diseases. Learn more at Media Contact Taylor AveiDirector of Business DevelopmentHalia Therapeuticsinfo@ View original content to download multimedia: SOURCE Halia Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 days ago
- Business
- Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS). Mesutoclax is an important global asset of InnoCare in the field of hematology. This approval marks the Company will initiate the clinical trial for the fourth indication of our BCL2 inhibitor. Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years). Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, 'Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible.' About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Yahoo
3 days ago
- Business
- Yahoo
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
BEIJING, May 29, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) in combination with azacitidine for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndromes (MDS). Mesutoclax is a novel, orally bioavailable BCL2 selective inhibitor. BCL2 is an important regulatory protein in the apoptosis pathway, and its abnormal expression is associated with the development of various hematologic malignancies. Mesutoclax exerts anti-tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal myeloid diseases characterized by the abnormal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myelodysplasia, ineffective hematopoiesis, peripheral-blood cytopenia, and a high risk of progression to acute myeloid leukemia (AML). The annual incidence of myelodysplastic syndromes is about 4 cases/100,000 people/year (reaching 40–50/100,000 in patients aged ≥ 70 years). Mesutoclax has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of BTKi-treated relapsed or refractory mantle cell lymphoma (R/R MCL). This marks the first BCL2 inhibitor to receive BTD recognition in China. The Company is accelerating patient enrollment of a Phase III registrational trial of mesutoclax in combination with orelabrutinib as a first line therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as a clinical trial of mesutoclax for the treatment of AML. Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "Mesutoclax is an important global asset of our company in the field of hematology. We are delighted to receive approval to initiate the clinical trial for the fourth indication of our BCL2 inhibitor. We will accelerate the clinical development of mesutoclax across multiple indications in China and globally to bring benefits to patients as early as possible." About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on Contacts Media Chunhua Investors 86-10-66609999ir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Faron's Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies
TURKU, FI / / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases antigen presentation and overcoming resistance to standard-of-care drugs Study highlights: Ex vivo treatment of AML and MDS bone marrow samples with bexmarilimab led to increased antigen-presenting human leukocyte antigen DR isotype (HLA-DR) expression, indicating improved antigen presentation capacity. Bexmarilimab , when combined with azacitidine or venetoclax, enhanced HLA-DR expression and in many samples, reduced the viability of leukemic blasts, particularly in venetoclax-resistant samples. The triple combination of bexmarilimab + azacitidine + venetoclax showed greater anti-leukemic effect in resistant AML cell lines than standard treatments alone. Turku, Finland - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, today announced the publication of a new peer-reviewed preclinical study in Scientific Reports , validating the immune-reprogramming and anti-leukemic potential of its investigational macrophage CLEVER-1 inhibitor, bexmarilimab , in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The study, conducted in collaboration with leading Finnish and Danish academic research centers, examined AML cell lines and bone marrow samples from patients with AML (n = 34) and MDS (n = 4) and showed that CLEVER-1 is highly expressed on malignant myeloid cells, especially in AML with monocytic differentiation. Immunotherapy treatments have revolutionized the treatment of many cancers but remain largely ineffective in AML and MDS due to immune resistance. Bexmarilimab addresses these challenges by reactivating the immune environment at its source (i.e. macrophages) and targeting CLEVER-1 directly on leukemic blasts. This approach represents a novel therapeutic avenue in myeloid malignancies where effective treatments are urgently needed. CLEVER-1, a scavenger receptor involved in immunosuppression, was found to be highly expressed on immature myeloid cells and their monocytic derivatives, particularly in AML cases with M4-M5 FAB subtypes and in Fms Related Receptor Tyrosine Kinase 3 (FLT3) and/or Nucleophosmin 1 (NPM1) mutations. "Our results show that CLEVER-1 is not only a macrophage checkpoint but also expressed on malignant myeloid cells and targeting it with bexmarilimab can enhance antigen presentation and sensitize these cells to standard therapies. These findings highlight a compelling opportunity to integrate bexmarilimab into standard treatment regimens for AML and MDS," said Dr. Maija Hollmén, Chief Scientific Officer of Faron and senior author of the study, MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland. Using ex vivo models, the team evaluated the effects of bexmarilimab , alone and in combination with standard-of-care therapies azacitidine and venetoclax, on immune activation and cell viability. Bexmarilimab monotherapy increased the expression of antigen-presenting HLA-DR by 1.2- to 2-fold in up to 66% of patient samples, especially in those with low baseline expression and high CLEVER-1 levels, without any cytotoxic effects on the blast cells, via potentially inducing interferon gamma (IFNg). Addition of bexmarilimab helped overcome venetoclax-resistance in 33-40% of ex vivo AML samples, without adding to lymphocyte toxicity. Moreover, the triplet of bexmarilimab, azacitidine, and venetoclax showed enhanced cytotoxicity in ex vivo models of treatment-resistant AML; suggesting that bexmarilimab increases the susceptibility to venetoclax and/or azacitidine induced cell death. "This is an important milestone in our mission to bring the benefits of macrophage checkpoint inhibition to patients with hematological cancers like AML and MDS, especially after disease relapse," said Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals. "The results strongly support the clinical rationale for combining bexmarilimab with standard therapies and also offer compelling evidence that our approach is both scientifically robust and clinically relevant, guiding the continued advancement of our BEXMAB trial." The ongoing BEXMAB clinical study is currently evaluating bexmarilimab in combination with azacitidine in relapsed/refractory AML and MDS patients. The trial's most recent phase II data, to be presented at ASCO and EHA 2025, showed promising response rates in pretreated populations. Faron will be hosting a virtual webinar to discuss the full analysis of r/r MDS as well as new frontline HR MDS patient data on Monday, 2 June 2025. To register for the event visit: BEXMAB Phase II study results For more information, please contact: IR Partners, Finland(Media)Riina TuominenKare Laukkanen +358 44 313 50 553 9535 / +44 7 469 766 FINN Partners, US(Media) Alyssa Paldo +1 847 791-8085 Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä +358 (0)40 555 4727+358 (0)50 553 8990 About BEXMABThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About bexmarilimabBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals LtdFaron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab , a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire
